Literature DB >> 11280926

Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.

K Blum1, E R Braverman, J M Holder, J F Lubar, V J Monastra, D Miller, J O Lubar, T J Chen, D E Comings.   

Abstract

The dopaminergic system, and in particular the dopamine D2 receptor, has been implicated in reward mechanisms. The net effect of neurotransmitter interaction at the mesolimbic brain region induces "reward" when dopamine (DA) is released from the neuron at the nucleus accumbens and interacts with a dopamine D2 receptor. "The reward cascade" involves the release of serotonin, which in turn at the hypothalmus stimulates enkephalin, which in turn inhibits GABA at the substania nigra, which in turn fine tunes the amount of DA released at the nucleus accumbens or "reward site." It is well known that under normal conditions in the reward site DA works to maintain our normal drives. In fact, DA has become to be known as the "pleasure molecule" and/or the "antistress molecule." When DA is released into the synapse, it stimulates a number a DA receptors (D1-D5) which results in increased feelings of well-being and stress reduction. A consensus of the literature suggests that when there is a dysfunction in the brain reward cascade, which could be caused by certain genetic variants (polygenic), especially in the DA system causing a hypodopaminergic trait, the brain of that person requires a DA fix to feel good. This trait leads to multiple drug-seeking behavior. This is so because alcohol, cocaine, heroin, marijuana, nicotine, and glucose all cause activation and neuronal release of brain DA, which could heal the abnormal cravings. Certainly after ten years of study we could say with confidence that carriers of the DAD2 receptor A1 allele have compromised D2 receptors. Therefore lack of D2 receptors causes individuals to have a high risk for multiple addictive, impulsive and compulsive behavioral propensities, such as severe alcoholism, cocaine, heroin, marijuana and nicotine use, glucose bingeing, pathological gambling, sex addiction, ADHD, Tourette's Syndrome, autism, chronic violence, posttraumatic stress disorder, schizoid/avoidant cluster, conduct disorder and antisocial behavior. In order to explain the breakdown of the reward cascade due to both multiple genes and environmental stimuli (pleiotropism) and resultant aberrant behaviors, Blum united this hypodopaminergic trait under the rubric of a reward deficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11280926     DOI: 10.1080/02791072.2000.10736099

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  258 in total

Review 1.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

Review 2.  The neural circuitry of reward and its relevance to psychiatric disorders.

Authors:  David T Chau; Robert M Roth; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

Review 3.  The biochemical bases of the placebo effect.

Authors:  Raúl de la Fuente-Fernández; A Jon Stoessl
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 4.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat.

Authors:  David T Chau; Jibran Y Khokhar; Ree Dawson; Jayme Ahmed; Haiyi Xie; Alan I Green
Journal:  Alcohol       Date:  2013-10-17       Impact factor: 2.405

Review 6.  Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment.

Authors:  Rebecca J Houston; Nicolas J Schlienz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-09-23

7.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Margaret A Madigan; Lyle Fried; Eric R Braverman; John Giordano; Rajendra D Badgaiyan
Journal:  Glob J Addict Rehabil Med       Date:  2017-02-23

8.  Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes.

Authors:  Bryan Cruz; Rodolfo J Flores; Kevin P Uribe; Evangelina J Espinoza; Charles T Spencer; Katherine M Serafine; Arbi Nazarian; Laura E O'Dell
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

9.  Frontostriatal network dysfunction as a domain-general mechanism underlying phantom perception.

Authors:  Jeffrey Hullfish; Ian Abenes; Hye Bin Yoo; Dirk De Ridder; Sven Vanneste
Journal:  Hum Brain Mapp       Date:  2019-01-15       Impact factor: 5.038

10.  Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8-15 years: National Health and Nutrition Examination Survey 2001-2004.

Authors:  H C M Byrd; C Curtin; S E Anderson
Journal:  Pediatr Obes       Date:  2013-01-16       Impact factor: 4.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.